Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity

Huabin Zhu, Henrique Lemos, Brinda Bhatt, Bianca N. Islam, Abhijit Singh, Ashish Gurav, Lei Huang, Darren D. Browning, Andrew Mellor, Sadanand Fulzele, Nagendra Singh

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory genes in peripheral and central nervous system (CNS), infiltration of immune cells into brain, and increased numbers of activated/memory T cells. Animal models of PD have shown a critical role of T cells in inducing pathology in CNS. However, the effect of carbidopa on T cell responses in vivo is unknown. In this report, we show that carbidopa strongly inhibited T cell activation in vitro and in vivo. Accordingly, carbidopa mitigated myelin oligodendrocyte glycoprotein peptide fragment 35–55 (MOG-35-55) induced experimental autoimmune encephalitis (EAE) and collagen induced arthritis in animal models. The data presented here suggest that in addition to blocking peripheral conversion of levodopa, carbidopa may inhibit T cell responses in PD individuals and implicate a potential therapeutic use of carbidopa in suppression of T cell mediated pathologies.

Original languageEnglish (US)
Article numbere0183484
JournalPloS one
Issue number9
StatePublished - Sep 2017

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity'. Together they form a unique fingerprint.

Cite this